| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.7, with a high estimate of $75.00 and a low estimate of $42.00. Marking an increase of 50.47%, the current average surpasses the previous average price target of $43.00.
A comprehensive examination of how financial experts perceive CG Oncology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Corinne Johnson | Goldman Sachs | Raises | Buy | $50.00 | $43.00 |
| Corinne Johnson | Goldman Sachs | Announces | Buy | $50.00 | - |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $75.00 | - |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $75.00 | - |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Announces | Overweight | $75.00 | - |
| Corinne Johnson | Goldman Sachs | Announces | Neutral | $42.00 | - |
| Jeffrey Hung | Morgan Stanley | Announces | Overweight | $55.00 | - |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CG Oncology's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on CG Oncology analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: CG Oncology's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 172.68%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3200.76%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CG Oncology's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -7.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CG Oncology's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CGON
